Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies.

n/a --- primary cilia --- neurodegeneration --- nutrient sensor --- PI3K --- transcriptomics --- phosphorylation --- metabolic reprogramming --- autophagy --- Alzheimer’s disease --- rapalogs --- liver --- angiogenesis --- mTOR complex --- MBSCs --- advanced biliary tract cancers --- Medulloblastoma --- epithelial to mesenchymal transition --- AMPK --- p70S6K --- lipid metabolism --- thyroid cancer --- sodium iodide symporter (NIS)/SLC5A5 --- male fertility --- anesthesia --- illumina --- mTOR inhibitor --- miRNA --- Hutchinson-Gilford progeria syndrome (HGPS) --- eIFs --- Emery-Dreifuss muscular dystrophy (EDMD) --- glucose --- AKT --- oral cavity squamous cell carcinoma (OSCC) --- glucose and lipid metabolism --- cellular signaling --- aging --- tumor microenvironment --- rapamycin --- leukemia --- chloral hydrate --- rapalogues --- schizophrenia --- T-cell acute lymphoblastic leukemia --- senescence --- lamin A/C --- neurotoxicity --- neurodevelopment --- inhibitor --- methamphetamine --- pulmonary fibrosis --- mTOR --- mTOR inhibitors --- combination therapy --- proteolysis --- fluid shear stress --- tumour cachexia --- biomarkers --- synapse --- gluconeogenesis --- mTOR signal pathway --- Sertoli cells --- immunosenescence --- miRNome --- protein aggregation --- senolytics --- metabolism --- NGS --- mTORC2 --- mTORC1 --- metabolic diseases --- IonTorrent --- apoptosis --- dopamine receptor --- nocodazole --- microenvironment --- everolimus --- acute myeloid leukemia --- immunotherapy --- spermatogenesis --- bone remodeling --- signalling --- targeted therapy --- ageing --- therapy --- NVP-BEZ235 --- fructose --- physical activity --- laminopathies --- MC3T3-E1 cells --- cell signaling --- microRNA --- cancer --- lipolysis --- melatonin --- Parkinson’s disease --- Alzheimer's disease --- Parkinson's disease

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Breast cancer is acknowledged as an international priority in healthcare. It is currently the most common cancer in women worldwide, with demographic trends indicating a continuous increase in incidence. Over the years, increasing efforts and resources have been devoted to the search for a systematic and optimized strategy in breast cancer diagnosis and treatment. Today, the Breast Unit model is considered the gold standard in order to ensure optimal patient-centered and research-based clinical services through multidisciplinary and integrated management.Surgical treatment has gradually evolved toward less aggressive approaches with the adoption of new therapeutic strategies. The evolution of evidence-based guidelines in such leading disciplines as radiation and medical oncology has led to a steady improvement in survival rates. This Special Issue will highlight innovations in the integrated management of breast cancer, their potential advantages, and the many open issues that still need to be properly defined and addressed.

Medicine --- Pharmacology --- metastatic breast cancer --- breast surgery --- immune system --- metabolic derangements --- precision medicine --- integrated therapies --- advanced breast cancer --- mTOR inhibitor --- CDK4/6 inhibitor --- endocrine resistance --- breast cancer --- pregnancy --- chemotherapy --- tailoring --- personalization --- DataMart --- real world data --- predictive model --- healthcare --- breast-conserving surgery --- non-palpable breast lesions --- image-guided localization --- preoperative breast localization --- breast ultrasound --- large database --- standardized data collection --- networks --- nipple-sparing mastectomy --- immediate breast reconstruction --- acellular dermal matrix (ADM) --- aesthetic and oncological outcomes --- quality of life --- rare breast cancer --- osteoclast-like giant cells --- gene profiling --- Oncotype Dx --- adjuvant treatment --- neoadjuvant chemotherapy --- sentinel lymph node --- systemic treatment --- locally advanced breast cancer --- mini-invasive treatment --- liver metastases --- hepatic surgery --- personalized medicine --- sarcopenia --- physical performance --- frailty --- older cancer patients --- clinical trial --- patient enrollment --- artificial intelligence --- machine learning --- lung cancer --- oncology --- web app --- conventional CT and CT angiography --- DIEP flap planning --- multidisciplinary treatment --- evidence-based medicine --- personalized treatment --- oncological outcomes --- patient quality of life --- normal breast --- breast pathology --- hormone receptor --- hormone expression --- lymphedema --- lymphaticovenous anastomosis --- vascularized lymph node transfer --- lymphatic microsurgery --- radiotherapy --- oligometastatic breast cancer --- locoregional therapy --- CDK4/6 inhibitors --- multidisciplinary --- AMH --- ovarian reserve --- pregnancy desire --- subtypes breast cancer --- miRNAs --- breast cancer treatment --- next-generation-sequencing --- target therapy --- old age --- survival --- vitamin D --- ductal breast cancer --- in situ breast cancer --- lobular breast cancer --- histology